  |
||||||
 |
||||||
 GfK Healthcare: Designed to Boost Client Efficiencies and Support the Changing Industry
According to Richard B. Vanderveer, Ph.D.,
Chief Executive Officer, GfK Healthcare, "The
practice of medicine will be changing because
it needs to. Pharma companies will be
evolving into health care companies - and
marketing research must change to meet their
needs."
This desire to better meet clients' needs
through efficient marketing research and
support the industry in a time of great
change are the primary reasons behind the
merging of the former marketing research
operations of GfK Market Measures, GfK
Strategic Marketing and GfK V2 to form GfK
Healthcare, as discussed by Dr. Vanderveer
and Barry Zimmerman, President and Chief
Operating Officer, in a recent
Pharma Market Research Report article.
 The Innovator's Prescription
This month's published document for The
Orange Pages discusses the problems plaguing
our domestic and worldwide health care
systems and the potential solutions offered
by Clayton M. Christensen in his new book
The Innovator's Prescription.
A major flaw the author sees in the current
health care delivery system is that most
medicine is practiced on an intuitive basis.
That is, a very intelligent and well-trained
physician serves as the central collection
point for observations, test data, scans,
etc., and decides the appropriate therapy to
treat what in many cases is a broad and
presumptive diagnosis. According to the
author, in our haste to discover
one-size-fits-all blockbuster products, we
have failed to develop specific diagnostic
markers that will tell us which patients will
respond to which drugs. Christensen foresees
an era of precision medicine with more
emphasis on matching diagnostic testing and
therapeutic intervention to improve on our
current hit rate.
Managed Markets Landmark Tour: The Most Direct Route to Optimizing Your Strategic Plan
Free Educational Webcast:
Feb. 25, 2:00 - 3:15 p.m. EST Save the Date! What if you could peek into the managed
markets world as you've never seen it before?
Where you can get inside the minds of key
managed care organization decision makers and
make your way nonstop to action-ready
insights that will enable you and your
managed markets account team to create,
reshape or refine your strategic plan? What
if, along the way, you received information
you could leverage to enhance the
effectiveness of your programs so they
resonate with your target audience?
Join us for this unique opportunity to ensure
your managed care account team is on the most
effective route to success at GfK
Healthcare's upcoming webcast, Managed
Markets Landmark Tour: The Most Direct Route
to Optimizing Your Strategic Plan.
The Perfect Storm in Pharmaceutical Marketing Research: GfK's Workshop at the PMRG 2009 ANC
We invite you to join GfK Healthcare
March 8-10 in Las Vegas at the Pharmaceutical
Marketing Research Group's Annual National
Conference (ANC), Maximizing Brand
Potential in a Volatile Marketplace. The
event promises to be an engaging exploration
of the increasing pressure placed upon
marketing researchers to maximize their
research dollars and overall potential.
On Monday, March 9 at 12:45 p.m., Richard B.
Vanderveer, Ph.D., CEO of GfK Healthcare,
will examine this volatility more closely and
present a workshop titled "The Perfect Storm
in Pharmaceutical Marketing Research - and
What to Do About It."
Did You Miss the January Issue of Topline?
Click
here to read the issue, which
includes:
Topline
archive is available. Skim the
directory and select
articles you missed. Access subscriber
opt-in/comment form.
|
 |
|
|
February 2009
 What Happens When Three Become One? As many of you know, GfK has, as of Jan. 15, taken its three health care companies, GfK Market Measures, GfK Strategic Marketing and GfK V2, and joined them into one entity - GfK Healthcare. As we progressed through 2008, a very important reason emerged for forming this union, and much of the year was spent figuring out how to optimize the synergies among the three companies. Quite simply, when GfK acquired NOP in 2005, it made sense to us, although we were bringing the companies together to constitute the GfK health care representation in the United States, to allow them to operate independently in a number of different ways. First, we allowed GfK V2 to retain its individual identity, believing, and I think correctly, that this brand carried substantial equity. We also revivified the corporate identities of Market Measures and Strategic Marketing, adding GfK to each of their corporate names to demonstrate their connection to each other and to the corporate entity based in Nuremberg, Germany. Although we met regularly and exchanged ideas, on a day-to-day basis the companies largely operated independently. Each had its own strengths and weaknesses, its own brand identity and its own loyal following of clients. But most importantly, at the time pharmaceutical marketing research was largely conceptualized of and conducted at a level of project size well within the scope of each of these companies. More recently, although much of marketing research still focuses on helping our product team beat the competition, health care marketing research has turned to bigger issues. Managed care, multitier co-pays, patient compliance and globalization have become issues that are increasingly put under the microscope of managed care...  Richard B. Vanderveer, Ph.D. CEO, GfK Healthcare    Research Highlight: Neurology
Data Download provides highlights of recently released data from GfK Healthcare's Therapeutic Class Studies (TCS). Based on primary market research, TCS provide in-depth analysis of market trends, physician practice patterns and competitive brand positioning. This month's selection covers research from studies conducted in the area of neurology. |
||
        
|
||||||